Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was inc… Read more
Market Cap & Net Worth: Respiratorius AB (publ) (HF00)
Respiratorius AB (publ) (F:HF00) has a market capitalization of $819.31K (€798.18K) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #36674 globally and #4551 in its home market, demonstrating a -0.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Respiratorius AB (publ)'s stock price €0.10 by its total outstanding shares 7902748 (7.90 Million).
Respiratorius AB (publ) Market Cap History: 2026 to 2026
Respiratorius AB (publ)'s market capitalization history from 2026 to 2026. Data shows growth from $819.31K to $819.31K (0.00% CAGR).
Respiratorius AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Respiratorius AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HF00 by Market Capitalization
Companies near Respiratorius AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Respiratorius AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Respiratorius AB (publ) Historical Marketcap From 2026 to 2026
Between 2026 and today, Respiratorius AB (publ)'s market cap moved from $819.31K to $ 819.31K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €819.31K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Respiratorius AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $819.31K USD |
| MoneyControl | $819.31K USD |
| MarketWatch | $819.31K USD |
| marketcap.company | $819.31K USD |
| Reuters | $819.31K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.